PSTEIN-BARR VIRUS (EBV), a widespread human
herpesvirus, displays unique transforming ability for B cells in vitro.' Clinically, EBV causes acute infectious mononucleosis in primary infection, a mostly benign lymphoproliferative syndrome induced by virus-infected B-cell expansion, and has a close etiologic relation to several human B-cell malignancies such as endemic Burkitt's lymphoma (BL) and B lymphomas in immunocompromised hosts.' However, EBV is also implicated in the development of non-B -cell neoplasms: nasopharyngeal carcinoma,' certain T-cell lymphomas,2" Hodgkin's thymic cancer,' gastric carcinoma,'.y and, more recently, smooth-muscle tumors in immunosuppressed patients.'".' ' In addition to these EBV-related human tumors of heterogeneous tissue origin, there is another life-threatening illness with unusual EBV activation-severe chronic active EBV infection (SCAEBV).12 Patients with SCAEBV suffer from a variety of serious symptoms over months to several years and subsequently contract fatal sequela such as opportunistic infection or multiple organ f a i l~r e . '~, '~ EBV indeed causally gene and EBV episomal structures similar t o those of AIK-T4 were not found in its source PBL, probably due t o the few parental clones in vivo. All lines expressed EBV-encoded small RNA (EBER) 1, nuclear antigen (EBNA) 1, and latent membrane protein (LMP) 1, -2A, and -28, but not other EBNAs that could be recognized by EBV-specific immune T cdls. EBV replicative antigens were rarely expressed or induced. Such EBV latency reflects the in vivo situation, in which the T cells may evade immune surveillance and be insensitive t o antiherpesvirus drugs. Collectively, the data suggest that EBV can target and latently infect T cells at any stage of differentiation in vivo, thus potentially causing uncontrolled T-cell proliferation. These cell lines will facilitate further analyses of possible EBV-induced oncogenicity in T cells. 0 1996 by The American Society of Hematology.
participates in the illness, as evidenced by large amounts of EBV genomes andor antigens in affected tissues with abnormal immunologic responses to the virus'2.'3; however, the pathogenesis of this type of EBV infection is still unclear.
There have been reports and we have made unpublished observations of SCAEBV due to EBV-infected T-cell proliferation, which often showed monoclonality or oligoclonality; in these cases the prognosis is usually p00r.'~"~ Such detected clonality and high rate of mortality may reflect an evolutionary phase of the T cells moving into the neoplastic state, although the histology of involved tissues often lacks malignant finding^.'^.'^.'^. '' In contrast with the accumulated clinical evidence suggesting an association of EBV with neoplastic T-cell proliferation," only a few investigations have so far been made to validate T-cell proliferation induced by EBV.2"-23 To study the poorly understood EBV-T-cell interaction(s), two approaches may be useful: to establish an in vitro system for EBV infection of primary T-lineage cells and to obtain a spontaneous cell line that represents EBV-infected T cells proliferating in vivo. However, the paucity of EBV-susceptible primary T cells and EBV-carrying T-cell lines hinder analyses of EBV-induced phenomena in a T-cell background.
We describe here four novel EBV-carrying cell lines established from patients with SCAEBV. The cell lines were characterized by virologic and immunologic methods, thereby showing that all the lines comprised EBV-carrying and -expressing clonal T cells with various differentiations. These rare T-cell lines may contribute to studying EBV biology in a T-cell environment and the pathogenesis of an uncontrolled disease, SCAEBV associated with T-cell proliferation.
MATERIALS AND METHODS

Patients and Source of Cell Lines
The cell lines described here originated from three Japanese pediatric patients with SCAEBV associated with T-cell proliferation. Their clinical and virologic data are summarized in Table 1 . The clinical manifestations and remarkably high serum antibody titers to EBV had persisted for more than 6 months. The diagnosis of SCAEBV was made based on the detection of EBV-determined nuclear antigen 1 (EBNA1)-positive cells and the large amount of EBV DNA in involved tissues. The patients were seronegative for human T-cell lymphotropic virus type I (HTLV-I) and human immunodeficiency virus type 1 (HIV-l). Histologic examination of biopsied lymph nodes showed reactive findings. Cryopreserved peripheral blood lymphocytes (PBL) taken within 7 months &er onset of the disease were used for culture. All clinical samples were obtained after informed consent of the patients' parents and used according to the guidelines of the Committee for Experimentation and Protection of Human Subjects, Cancer Institute, Hokkaido University School of Medicine.
Culture Conditions
The patients' PBL stored in liquid nitrogen were thawed and suspended at 1 X 106/mL in RPM1 1640 medium supplemented with 20% heat-inactivated fetal calf serum or 15% pooled human AB type sera, 2 mmoVL L-glutamine, 1 mmolR. sodium pyruvate, 0.1 mmolR. nonessential amino acids (GIBCO BRL, Gaithersburg, MD), 2 mmovL HEPES, 50 U/mL penicillin, and 50 pg/mL streptomycin, and seeded into a 96-well culture plate. We prepared four different culture media for each patient's PBL specimen: media containing recombinant human interleukin-2 (rIL-2; Shionogi, Osaka, Japan; 50 U/mL), 12-0-octa-(2,4)-dienoyl-4-deoxy-4 P-phorbol-13-acetate (4-deoxyphorbol ester; 0.4 ng/mL), either rIL-2 or 4-deoxyphorbol ester alone, and with no addition. 4-Deoxyphorbol ester is a naturally occurring substance extracted and purified from the plant Euphorbia tirucalli, which grows densely in BL-endemic areas of East Africa.z4 This substance is a possible environmental risk factor for the local endemicity of African BL, based on its notable enhancing effects on EBV-induced B-cell transformation in vitr0.2~ During incubation at 37°C in 5% CO2 humidified conditions, the cultures were regularly checked for EBNAl by anticomplement immunofluorescence using seropositive reference human serum (anti-EBNAl titer of 1:1280)9 and for EBV genomes by polymerase chain reaction (PCR) or in situ hybridization (see below).
Morphologic and Immunophenotype Analyses
Cell morphology was examined by Wright-Giemsa staining. Cell phenotypes were investigated by indirect immunofluorescent staining with various monoclonal antibodies (MoAbs; Table 2 ) followed by flow cytometric analysis (FACScan Cytometer; Becton Dickinson Immunocytometry System, Mountain View, CA). Cord blood Blymphoblastoid cell lines (LCL) immortalized with the 895-8 strain of EBV?' TALL-lz6 (Japanese Cancer Research Resource Bank, Tokyo, Japan), and MUMC-2" were used as controls. To search for the EBV receptor on cell surfaces, an EBV adsorption assay was also performed by using fluorescein-isothiocyanate (F1TC)-labeled virus.2'
DNA-PCR
The established cell lines were tested by PCR for the following virus genomes: EBV, herpes simplex virus type 1 and type 2, varicella-zoster virus, cytomegalovirus, human herpesvirus 6 (HHV-6), HHV-7, HTLV-I, and HIV-1.
Briefly, after one-step DNA extraction from lo5 cells,28 PCR was performed with 20 cycles of amplification for 125-bp EBV BamHI-W, 25 cycles for 269-bp EBV BamHI-K, and 30 cycles for the other virus genomes in a DNA thermal cycler (Perkin Elmer Cetus, Norwalk, CT). The reaction conditions and primer-probe combinations used are described elsewhere.28-"
Genotypic Analysis
Immunogenotyping of the cell lines and their clinical sources was performed by Southern blot hybridization. Extracted DNA was digested with appropriate restriction enzymes, electrophoresed on 0.6% agarose gels, and transferred onto Hybond-N' nylon membrane (Amersham Japan, Tokyo, Japan). The filters were then hybridized with the "P-labeled TCRP (Cg2),32 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From performed to investigate EBV integration into the cellular DNA, a few events of which have been reported to occur at the termini or within the BamHI-C The probes were "P-labeled by random priming or 3'-end-labeling.
Analysis of EBV Gene Expression
In situ hybridization. In situ hybridization was performed using a digoxigenin (DIG)-labeled antisense oligonucleotide probe (5'-TACAAGTCCCGGGTGGTGAGGACGGTGTCT-3'; genome coordinates 6697-6726) or sense probe to EBER1.6 Cells were fixed with freshly prepared 4% paraformaldehyde/O.l m o m phosphate buffer (PB; pH 7.4) overnight at 4"C, smeared onto 3-aminopropylethoxysilane-coated slides, and air-dried. After brief washing with 0.1 moln PB, the slides were treated with 10 pg/mL proteinase K for 30 minutes at 37"C, refixed with 4% paraformaldehyde/O.l mol/ L PB for 30 minutes at room temperature, washed with 0.1 m o m PB for 5 minutes, acetylated with 0.25% acetic anhydridel0.l mol/ L triethanolamine-HC1 (pH 8.0) for 10 minutes, and washed again with 0.1 m o m PB. They were then dehydrated with ethanol series, air-dried, and subjected to prehybridization. Hybridization was performed overnight at 42°C in a buffer consisting of 50% deionized formamide, 3 x SSC, 20 mmoVL PB, 10% dextran sulfate, 1X Denhardt's solution, 100 pg/mL of sonicated salmon sperm DNA, 125 pg/mL of Yeast t-RNA (Sigma, St Louis, MO), and 100 pmoUmL of the DIG-labeled probe. Then the slides were washed with 5X SSC briefly and with 0 . 2~ SSC for 15 minutes at 60°C three times. Hybridized probes were detected by using a DIG Nucleic Acid Detection Kit (Boehringer, Mannheim, Germany) according to the manufacturer's instructions.
tmmunojuorescence. EBNA 1 expression was examined by anticomplement immunofluorescence? Expression of EBNA2, latent membrane protein 1 (LMPI) and EBNA leader protein (LP) was assessed by streptavidin-biotin immunofluorescence with MoAbs PE2," CS 1 -4,39 and JFl86," respectively. EBV replication-associated antigens were stained by indirect immunofluorescence with the following MoAbs: BZ.14' (Dakopatts) specific to the immediateearly BZLFl gene product (also called ZEBRA), R342 to the early antigen-diffuse component (EA-D), C84443 to the EA-restricted component (EA-R), and C30 (unpublished data) to the viral capsid antigen (VCA). Furthermore, cells were examined for inducibility of EBV replication by treatment with 12-0-tetradecanoyl-phorbol-13-acetate (TPA; Sigma) and n-butyrate, known activators of latent EBV in B cells.44 Briefly, 5 X lo5 cells were incubated with or without 20 ng/mL TPA and 4 mmolfL n-butyrate for 36 hours and stained with MoAbs to BZLFUZEBRA, EA-D, EA-R, and VCA. B95-8 cells and Raji cells, in which the latent EBV is highly activated by the chemicals,M served as positive controls.
tmrnunoblotting. Protein extraction, electrophoresis, blotting, and detection were performed as previously described?," LCL and Molt-4 cells were used as EBV-positive and -negative cell controls, respectively. EBV-seronegative human serum and normal mouse Ig (Dakopatts) were included as negative antibody and isotype controls, respectively.
Reverse transcription-P CR (RT-P CR). Total cellular RNA was isolated from 5 X lo6 cells with guanidium isothiocyanate-phenol extraction (TRIzol; GIBCO BRL) according to the manufacturer's protocol. Extracted RNA was divided into aliquots, heated for 5 minutes at 90°C and rapidly cooled on ice, and then cDNA synthesis was performed for 60 minutes at 37°C with Molony murine leukemia virus RTase (GIBCO BRL) using 10 pmol of a 3' primer specific for EBNAI, -2, LMP1, -2A, and -2B mRNAs, followed by 10 minutes of heating at 94°C. The cDNA samples were then subjected to 35 cycles of PCR in a thermal cycler by the hot-start method. Each cycle consisted of denaturation for 1 minute at 94"C, annealing for 2 minutes at 55"C, and extension for 2 minutes at 72°C. The reaction mixture contained buffers and reagents as described," with 20 pmol of each primer and cDNA (equivalent to 5 X l@ celldtube) in a volume of 100 pL. Full details of primers and probes used are given in Table 3 . Ten microliters of the PCR products was electrophoresed on a 2% agarose gel, Southern transferred onto nylon membranes, and specific amplified DNA was detected by a "P-end-labeled probe. The quality of RNA was checked by parallel amplification of cytoplasmic 8-actin mRNA.& RNAs from LCL and BJAB cells were used as EBV-positive and -negative controls, respectively. Transfer of EBV to primary B lymphocytes. Each established line (10' cells) was treated with TPA/n-butyrate as described above, thoroughly washed, irradiated (90 Gray, "CO source), and then cocultured with lo6 B-cell-enriched cord blood lymphocytes for 8 weeks. The resultant LCLs were confirmed to express EBNAl and B-lineage-specific antigen CD20, but not other lineage markers.
RESULTS
Establishment of Cell Lines
Culture of the patients' PBL resulted in cell growth with a concomitant increase of EBNAl-positive cells only in the culture containing rL-2 plus 4-deoxyphorbol ester. Initially, cell growth was noted also in the culture containing rIL-2 alone; however, the proportion of EBNAl-positive cells gradually declined. Cells did not grow in the cultures containing 4-deoxyphorbol ester alone or in the control culture. As shown in Fig 1, the representative kinetic data from culture showed a simultaneous increase of EBNAl+ and CD3+ cells, but not CD19' cells, in the presence of rL-2 and 4-deoxyphorbol ester. At 3 to 4 weeks postinitiation of culture, when EBNAl positivity reached more than 95%, the EBNAl-expressing cells continued to proliferate even in the absence of 4-deoxyphorbol ester. Although the cells were then cultured as an uncloned population for a while, they became 100% positive for EBNAl and T-cell markers thereafter. EBV genome carriage was confirmed by PCR (data not shown) and in situ hybridization for EBERl (Fig 1 and  see below) . The three established cell lines were designated SIS, AIK, and SKN at that time and several clones were isolated later from SIS and SKN by limiting-dilution.
Cell Phenotype and Morphology
Phenotypic analysis showed that the SIS line was positive for CD2, CD3, and CD4 antigens and that the SKN line was positive for CD2 but not CD3, CD4, or CD8 antigens ( Fig  2 and Table 2 ). Neither of them expressed B-cell-specific CD19 or CD20, NK-cell-associated CD56 or CD57, or monocyte or myeloid lineage-associated CD13, CD14, CD16, or CD34 antigens (Fig 2 and Table 2 ). Their phenotypes were similar to those of EBNAl-expressing cells in their source PBL, as previously determined (Table 1 ). All clones obtained from SIS and SKN also showed the same phenotypes (data not shown). Interestingly, the AIK cell line was initially judged to comprise only CD2+/CD3+/CD4-/ CD8+ cells; however, phenotypic alteration to a mixture of CD4+ and CD8+ populations was noted 2 months postestablishment, although EBNA1, CD2, and CD3 were still detected in 100% of the cells. Thus, another stored PBL sample The coordinates were according to the sequence of the prototype 895-8 EBVZ and the predicted sizes of amplified products were calculated by the known spliced structure of each mRNA. The 3' primer L2-3 and probe L2-2 were commonly used for detection of both LMP2A and LMPZB transcripts.
of the AIK patient was re-examined carefully for the phenotype of EBNAl-expressing cells, thereby showing that a quite small number of them were positive for CD4 (Table  1 ). The AIK cells were then separated into CD8+ and CD4' populations by anti-CD8 MoAb (L,eu-2a)-based magnetic bead (Dynabeads M-450; Dynal, Oslo, Norway) fractionation, and the two resultant sublines were newly designated AIK-T8 and AIK-T4, respectively. Neither AIK-T8 nor AIK-T4 possessed B, NK, monocyte, or myeloid lineagespecific antigens (Fig 2 and Table 2 ). None of the four cell lines expressed CD21 (EBV receptor/CR2) and bound FITClabeled EBV (Table 2) . Morphologically, the cell lines were typical lymphoblasts with several fine nucleoli and slightly basophilic cytoplasm (Fig 3) . All cell lines have been growing stably for more than 32 months in the presence of rIL-2 alone (20 U/mL).
Immunogenotypes of the Cell Lines
Southern blot analysis showed that SIS and AIK-T8 had clonal TCRB gene rearrangements, the bands of which were identical in size to those found in their source PBL (Fig 4) . Similar results for TCRy gene were obtained in SIS and Table 2 and isotype controls, respectively. The vertical axis denotes the cell number counted and the horizontal axis denotes fluorescence intensity (log scale). Table 1 ); R-AIK, PBL DNA of patient no. 2; Pt-SKN, DNA from a lymph node of patient no. 3. EeoRI-digested DNA was hybridized with the 32P- AIK-Tg (data not shown). AIK-T4 also had clonally rearranged TCRP and TCRy genes; however, corresponding bands were not found in its source material (Fig 4) . By contrast, there was no evidence of TCRP (Fig 4) , TCRy, and TCR6 gene rearrangements in SKN (data not shown). None of the four cell lines had Ig gene rearrangement (data not shown).
Analysis of Viral Genome
Southern hybridization of BamHI-digested DNA from each cell line with the Xho l-a probe detected a unique single terminal fragment band between 9.0 kb and 14 kb, but not a ladder of smaller bands (<6.0 kb) representing the linear EBV genome (Fig S) ." Rehybridization of the same blots with the EcoRI-I probe again yielded a single band identical to that detected by the Xhol-a probe (data not shown), suggesting that the cell lines carried EBV in a single episomal form. The BamHI-C probe identified the standard BamHI-C fragment in all four cell lines (data not shown). Taken together, the results represented a negative finding of EBV integration into the cellular DNA. SIS and AIK-T8 carried the same clonotypes of episomal EBV as their sources (Fig  S ) . Although two episomal bands were detected in a lymph node from the SKN patient, indicating biclonal proliferation in vivo, one of the bands coincided in size with that found in the SKN line (Fig S) . These results suggested that the S E , AIK-T8, and SKN lines were really derived from EBVinfected T-cell clones proliferating in the patients' bodies. AIK-T4 had the clonal EBV genome as well; however, a similar episomal band was not detected in its source PBL (Fig S ) , probably because the parental clone of AIK-T4 was too low in number to be detected by Southern hybridization. (This may also have been the case with TCR gene rearrangement; see Table l . ) The PCR test showed that none of the cell lines was infected with other herpesviruses. HTLV-I, or HIV-I (data not shown).
EBV Gene Expression
In situ hybridization showed that EBERI was abundantly transcribed in all four cell lines (Fig 6) and LCLs immortalized by the resident EBVs of SIS and AIK-T4 (data not shown). Immunofluorescence and immunoblot assays showed that all four cell lines expressed EBNAI and LMPI, but not other EBNAs (Fig 7A and B) . Consistent results were obtained by RT-PCR analysis, which produced additional evidence for LMP2A and -2B expression (Fig 8) . On the other hand, corresponding LCLs of SIS and AIK-T4 were found to express a full set of EBNAs and LMPI (Fig 7B; immunofluorescence data were not shown), signifying that the EBV strains carried in both lines were not defective for the genes encoding EBNA2, -3A, -3B, -3C. and LP. Transfer of EBV from AIK-T8 or SKN to cord blood B lymphocytes was unsuccessful. In all cell lines, spontaneous expression of EBV replicative antigens was detected in less than 0.2% of cells by immunofluorescence, even after treatment with TPA/n-butyrate (Table 4) .
DISCUSSION
Recent years have seen a renewal of interest in the association of EBV with T-lymphoproliferation owing to a number of reports of EBV-positive T lymphomas and SCAEBV associated with EBV-infected T-cell proliferation.".'.'"'" In contrast with this clinically based linkage. it is as yet largely unclarified whether EBV is actually involved in T-cell transformation or the oncogenic process because there are only a few publications concerning in vitro EBV infection of T-lineage cells or establishment of continuous T-cell lines harboring EBV.' "' ' ' Two experiments have achieved successful EBV infection of some leukemic and HTLV-I-infected T-cell lines."'," However, these results seem to be somewhat equivocal because the cells used were already immortalized without EBV. In this context, two previous researches using nonimmortalized T-lineage cells well illustrated the oncogenic potential of EBV in T cells.'"?'
Two EBV-positive cell lines with several T-lineage-associated antigens and TCR gene rearrangements were establi~hed."'.'~ However, because the cell lines simultaneously expressed B-cell-specific markers and Ig gene rearrangements, analysis of EBV biology in the T-cell environment was difficult. Recently, another EBV-carrying cell line that exclusively expresses T-lineage-specific antigens (CD2'/ CD3'/CD4-/CD8') and has TCR gene rearrangements was established by others from a patient with large granular lymphocyte leukemia."'This leukemic cell line phenotypically resembles our AIK-T8. Thus, the present paper is the second report on spontaneous EBV-positive cell lines of unequivocal T-cell origin. Also worth noting, the four Tcell lines we established showed individually distinct phenotypes in T-cell ontogeny: SIS and AIK-T4 with the mature helpedinducer phenotype, AIK-T8 with the mature suppres- sorkytotoxic phenotype, and SKN with the immature phenotype. To the best of our knowledge, no unique EBV-carrying T-cell line such as SIS, AIK-T4, or SKN has yet been reported.
The B-cell surface molecule CD21 was reportedly detected on several leukemic or HTLV-I-infected T-cell lines and a population of immature thymocytes, mature CD4', and CD8' T cells.s"~s' The CD21 expressed on certain thymocytes and HTLV-I-infected T-cell lines can act as a functional receptor for EBV.2'*2' However, CD21 was not detected on our cell lines even by using three different MoAbs, HB-5,0KB7, and B2, raising the possibility that the expression of CD21 might be downregulated after EBV entry into the cells, as exemplified by the EBV-infected but CD21-Bcell line P3HR-1.s4 Furthermore, an EBV adsorption assay was performed to investigate whether the possible infection mechanism occurred through anomalous CD21 or in a CD21-independent manner as with leukemic T-cell line HSB-22"; however, FITC-labeled EBV did not bind to any of our T-cell lines. Although it is still unclear exactly how EBV could infect the T cells, the successful establishment of a variety of EBV-positive T-cell lines supports the idea that EBV can target T-lineage cells at heterogeneous differentiation stages in vivo.
Among the hitherto identified EBV transformation-associated genes, our T-cell lines expressed EBERl, EBNA1, LMPl, -2A, and -2B, but not EBNA2, -3A, -3B, -3C, or LP, at the protein and mRNA levels. This form of EBV latency (called latency 11)" is similar to that seen in a subset of nasopharyngeal c a r~i n o m a , "~~~.~ Hodgkin's d i s e a~e , '~ and, as more recently reported, peripheral T-cell lymphomass6; thus, it is feasible that the genes selectively expressed might play important roles for T-cell transformation. Because EBV latent proteins other than EBNA1 can serve as target antigens for EBV-specific immune T ~e l l s~~.~* the downregulation of EBNA2, -3A, -3B, -3C, and LP may provide advantages for the EBV-infected T cells to evade immune surveillance, as well shown in BL.55 Yet the expression of LMPs suggests that the EBV-infected T cells are still sensitive at least to a certain population of EBV-specific immune T cells; therefore, patients with SCAEBV may have an immunologic defect(s) resulting in unresponsiveness to LMPs. Several studies showed impaired immune functions in SCAEBV, suggesting that the disease is pathogenetically analogous to EBV-induced B-cell proliferation arising in immunocompromised hosts.'2"9 If this is the case, immunologically unchecked polyclonal EBV-infected cells could occasionally evolve into a clonal proliferation during the SCAEBV course, as is seen in organ transplant recipients,60 and our T-cell lines may be the results of such in vivo events.
EBV seems to infect T cells mostly in a nonpermissive fashion, as shown by the absence of evidence for virus replication in our cell lines and their clinical sources, even after exposure to TPNn-butyrate. If such tight latency in vitro reflects the in vivo situation, it could imply the difficulty of treating EBV-induced T-cell proliferation with potent herpesvirus polymerase inhibitors such as acyclovir. Indeed, most cases of SCAEBV associated with T-cell proliferation can hardly be controlled by anti-herpesvirus drugs12 (unpublished observations). A case of SCAEBV successfully treated with intravenous m -2 was reported (the lineage of virus-infected cells was unknown)!' However, given that IL-2 is required, even if partially, for the stable growth of our T-cell lines, the cytokine should be used carefully to treat EBV-associated T-lymphoproliferative diseases. In fact, the patient from whom SKN was established drastically deteriorated right after rIL-2 treatment and consequently died (unpublished data).
It is now necessary to further analyze the EBV-T-cell interaction(s) and EBV-induced oncogenicity in T cells. which should offer novel approaches for studying the pathogenesis and treatment of EBV-associated T lymphoproliferation. In this regard, our T-cell lines will be useful subjects in vitro.
